

Product Update

atazanavir 150, 200 and 300mg capsules (Reyataz®) (No: 656/10) Bristol Myers Squibb Pharmaceuticals

05 November 2010

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

atazanavir (Reyataz®) is accepted for use within NHS Scotland.

Indication under review: atazanavir, co-administered with low dose ritonavir, is indicated for the treatment of paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.

Data available in children aged 6 to less than 18 years are very limited. Available data suggest that atazanavir in combination with ritonavir may not be effective in treatment experienced children even with very few (<3) protease inhibitor mutations. The choice of atazanavir in treatment experienced paediatric patients should be based on individual viral resistance testing and the patient's treatment history.

The Scottish Medicines Consortium has previously accepted this product for use in HIV infection in adults. Atazanavir is listed in the British National Formulary for Children 2010 - 11 for the treatment of HIV.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

*This assessment is based on data submitted by the applicant company up to and including **14 September 2010.***

**Chairman,
Scottish Medicines Consortium**